Basilea meldet für 2020 starke Finanzergebnisse und deutliche Fortschritte in ihrer klinischen Onkologie-Pipeline
February 16, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Zweistelliges Wachstum der direkt realisierten Umsatzbeiträge durch Cresemba und ZevteraBetriebsverlust um mehr als 50 % auf CHF 8.2 Mio. verringertUm 15% verbesserter Cashflow aus operativer...
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
February 16, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Double-digit growth in Cresemba and Zevtera non-deferred revenue contributionsOperating loss reduced by over 50% to CHF 8.2 millionImproved operating cash flow by 15%, CHF 167 million year-end cash...
Basilea kündigt Veräusserung ihres chinesischen F&E-Tochterunternehmens an PHT International an
February 15, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 15. Februar 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie eine Vereinbarung über die Veräusserung ihres chinesischen F&E-Tochterunternehmens Basilea Pharmaceutica...
Basilea announces divestment of its Chinese R&D subsidiary to PHT International
February 15, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, February 15, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D)...
Routemaster Capital Completes Acquisition of 20% Interest in Valour Structured Products, a Leading Exchange Traded Product Company Focused on Digital Assets
February 12, 2021 07:00 ET
|
Routemaster Capital Inc.
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (the “Company” or “Routemaster”) (NEO: DEFI GR: RMJR) is pleased to announce that it has closed the transaction to acquire 20% of...
Basilea präsentiert auf ASCO GU Symposium Dosisfindungs-Ergebnisse für Derazantinib/PD-L1-Checkpoint-Inhibitor-Kombination aus FIDES-02-Studie für Patienten mit soliden Tumoren
February 12, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 12. Februar 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass auf dem Symposium für urogenitale Krebserkrankungen der American Society of Clinical Oncology (ASCO GU 2021)...
Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium
February 12, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, February 12, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that data on the safety, tolerability and preliminary efficacy of the fibroblast growth factor...
Draganfly and Windfall Geotek Advance Testing of Drone-Based AI Solution for Landmine Detection
February 11, 2021 07:30 ET
|
Draganfly Inc
Los Angeles, CA., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and...
Basilea erreicht präklinischen Meilenstein im Rahmen einer Kooperation zur Entwicklung eines potenziellen First-in-Class Kinase-Inhibitors für die Krebstherapie
February 11, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 11. Februar 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie einen niedermolekularen Kinase-Inhibitor und potenziellen First-in-Class-Wirkstoff aus ihrem...
Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor
February 11, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, February 11, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has promoted a potential first-in-class small-molecule kinase inhibitor from its research...